Saturday, July 11, 2026

Drug profile · INN

hetacillin

hetacillin (VERSAPEN) is a penicillin-binding protein inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — hetacillin
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

hetacillin (VERSAPEN) is a penicillin-binding protein inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN hetacillin
Brand VERSAPEN
Mechanism Penicillin-binding protein inhibitor
Target Penicillin-binding protein
Route ORAL
Formulation FOR SUSPENSION

Mechanism of action

Penicillin-binding protein inhibitor

Primary target: Penicillin-binding protein

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. amoxicillin Bacterial penicillin-binding protein inhibitor
  2. ampicillin sodium Bacterial penicillin-binding protein inhibitor
  3. ampicillin/ampicillin trihydrate Bacterial penicillin-binding protein inhibitor
  4. cefaclor Bacterial penicillin-binding protein inhibitor
  5. cefadroxil/cefadroxil hemihydrate Bacterial penicillin-binding protein inhibitor
  6. cefazolin sodium Bacterial penicillin-binding protein inhibitor

Frequently asked questions

What is hetacillin?

hetacillin (VERSAPEN) is a penicillin-binding protein inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for hetacillin?

VERSAPEN is a marketed brand name for hetacillin. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of hetacillin?

hetacillin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.